The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended at its meeting on 23-26 February 2026 approval of 12 new medicines. Among them are mCombriax (mRNA vaccine from Moderna Biotech Spain) for immunization against influenza and COVID-19, Ojemda (tovorafenib from Ipsen Pharma) for the treatment of pediatric low-grade glioma, Onerji (levodopa/carbidopa from Tanabe Pharma GmbH) for the treatment of motor fluctuations in patients with Parkinson's disease, Rhapsido (remibrutinib from Novartis) for chronic spontaneous urticaria and Xolremdi (mavorixafor from X4 Pharmaceuticals) for WHIM syndrome. Other recommended drugs include Dazparda and others for the treatment of diabetes, Fubelv (etanercept biosimilar) for rheumatoid arthritis, and drugs for breast cancer. The CHMP issued a negative recommendation for Dayba (trophinetide from Acadia Pharmaceuticals). Drugs such as Dupixent (dupilumab), Jorveza (budesonide), Olumiant (baricitinib), Scemblix (asciminib) and Stelara received positive recommendations to expand indications, pending a decision by the European Commission. The application for Zumrad (sasanlimab by Pfizer) has been withdrawn.